Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3β.

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Tetramethylpyrazine (TMP) is recognized for its anticancer properties.
• The specific efficacy and molecular mechanisms of TMP in acute lymphoblastic leukemia (ALL) remain largely uncharacterized.
• Jurkat and SUP-B15 are commonly used ALL cell lines for research.

Purpose of the Study:

• To assess the anti-leukemic effects of TMP on Jurkat and SUP-B15 ALL cell lines.
• To elucidate the molecular pathways through which TMP exerts its anti-cancer effects in ALL.

Main Methods:

• Cell Counting Kit-8 (CCK-8) assay for proliferation analysis.
• Flow cytometry for cell cycle and apoptosis assessment.
• Quantitative real-time PCR and Western blot for gene and protein expression analysis of GSK-3β, NF-κB, c-myc, bcl-2, cox-2, survivin, and p27.

Main Results:

• TMP demonstrated dose- and time-dependent inhibition of Jurkat and SUP-B15 cell proliferation (IC₅₀ values: 120 and 200 µg/ml at 48h, respectively).
• TMP induced apoptosis and G0/G1 cell cycle arrest in both ALL cell lines.
• Treatment with TMP led to decreased expression of GSK-3β, NF-κB (p65), and c-myc, subsequently downregulating bcl-2, cox-2, and survivin, while upregulating p27.

Conclusions:

• TMP exhibits significant anti-proliferative and pro-apoptotic effects against ALL cell lines.
• The mechanism involves the downregulation of GSK-3β, inhibiting NF-κB and c-myc translocation, leading to cell cycle arrest and apoptosis.
• TMP represents a potential therapeutic agent for acute lymphoblastic leukemia.